Biocept Statistics
Total Valuation
Biocept has a market cap or net worth of $262. The enterprise value is $4.96 million.
| Market Cap | 262 |
| Enterprise Value | 4.96M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| Forward PS | 0.00 |
| PB Ratio | 0.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 39.97.
| Current Ratio | 1.81 |
| Quick Ratio | 1.52 |
| Debt / Equity | 39.97 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -156.61 |
Financial Efficiency
Return on equity (ROE) is -411.90% and return on invested capital (ROIC) is -279.08%.
| Return on Equity (ROE) | -411.90% |
| Return on Assets (ROA) | -104.00% |
| Return on Capital (ROIC) | -279.08% |
| Revenue Per Employee | $27,120 |
| Profits Per Employee | -$612,160 |
| Employee Count | 50 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 11.19 |
Taxes
| Income Tax | -125,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 43.58 |
| Average Volume (20 Days) | 397 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocept had revenue of $1.36 million and -$30.61 million in losses. Loss per share was -$50.90.
| Revenue | 1.36M |
| Gross Profit | -14.31M |
| Operating Income | -33.16M |
| Pretax Income | -30.73M |
| Net Income | -30.61M |
| EBITDA | -28.14M |
| EBIT | -30.54M |
| Loss Per Share | -$50.90 |
Balance Sheet
The company has $6.63 million in cash and $11.59 million in debt, giving a net cash position of -$4.96 million.
| Cash & Cash Equivalents | 6.63M |
| Total Debt | 11.59M |
| Net Cash | -4.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 290,000 |
| Book Value Per Share | n/a |
| Working Capital | 3.96M |
Cash Flow
In the last 12 months, operating cash flow was -$17.60 million and capital expenditures -$605,000, giving a free cash flow of -$18.20 million.
| Operating Cash Flow | -17.60M |
| Capital Expenditures | -605,000 |
| Free Cash Flow | -18.20M |
| FCF Per Share | -$17.56 |
Margins
Gross margin is -1,055.01%, with operating and profit margins of -2,445.28% and -2,257.23%.
| Gross Margin | -1,055.01% |
| Operating Margin | -2,445.28% |
| Pretax Margin | -2,266.45% |
| Profit Margin | -2,257.23% |
| EBITDA Margin | -2,075.29% |
| EBIT Margin | -2,252.06% |
| FCF Margin | -1,342.33% |
Dividends & Yields
Biocept does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -83.94% |
| Shareholder Yield | -83.94% |
| Earnings Yield | -11,682,442.75% |
| FCF Yield | -6,947,328.24% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biocept has an Altman Z-Score of -23.87 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.87 |
| Piotroski F-Score | 2 |